Leukemia / Lymphoma Clinical Trials

 

St. Jude Clinical Trials

ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Diseases Treated:

Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

Eligibility:

  • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
    • Come back after treatment the first time
    • Did not respond to treatment the first time
  • Less than 22 years of age
  • Does not have HIV or hepatitis B infection
View Trial

AML08: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Diseases Treated:

Acute myeloid leukemia (AML)

Eligibility:

  • 21 years of age or younger at the time of study entry
  • No prior therapy for AML except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine for hyperleukocytosis
  • Must not have Down syndrome, acute promyelocytic leukemia (APL), juvenile myelomonocytic leukemia (JMML), Fanconi anemia (FA), Kostmann syndrome, Shwachman syndrome and other  bone marrow failure syndromes
View Trial

BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

Diseases Treated:

Relapsed or refractory hematologic malignancies

Eligibility:

  • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
  • Must be 21 years of age or younger at the time of enrollment
  • Must have adequate kidney and heart function 
View Trial

HLHR13: Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

Diseases Treated:

High-risk Hodgkin lymphoma

Eligibility:

  • Has high-risk Hodgkin lymphoma
  • 18 years of age or younger
  • Has not received previous treatment for Hodgkin lymphoma
View Trial

HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

Diseases Treated:

Hodgkin lymphoma

Eligibility:

  • Diagnosis of early-stage Hodgkin lymphoma 
  • Hodgkin lymphoma that has not been previously treated
  • 21 years of age or younger
View Trial

MITREL: A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

Diseases Treated:

Refractory or relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Patient should be is less than or equal to twenty-one years of age.
  • Patient has a diagnosis of AML or MDS that has relapsed or is refractory to chemotherapy or has relapsed after HSCT.
  • Patient has an available HPC-A donor.
View Trial

NHL16: Study for Newly Diagnosed Patients with Acute Lymphoblastic Lymphoma

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed lymphoblastic lymphoma
  • Has received one week or less prior treatment for lymphoblastic lymphoma
View Trial

PANAML: Panobinostat, Fludarabine and Cytarabine in Patients with AML or MDS

Diseases Treated:

Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)

Eligibility:

  • Diagnosis of AML or MDS that has come back or did not respond to chemotherapy
  • 21 years of age or younger at time of enrollment
  • Able to swallow capsules
  • Recovered from side effects of previous cancer therapy
View Trial

RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

Diseases Treated:

Refractory or relapsed hematologic malignancies (leukemia)

Eligibility:

  • Between the ages of 1 and 25 years
  • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
  • No history of HIV infection, hepatitis B, or hepatitis C
View Trial

RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Diseases Treated:

Relapsed or refractory leukemia / lymphoma

Eligibility:

This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

View Trial

SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Diseases Treated:

Relapsed or refractory leukemia or hematologic malignancies

Eligibility:

  • Up to 21 years of age
  • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
  • No history of HIV infection
View Trial

SJBC3: Mature B-cell Lymphoma and Leukemia Study III

Diseases Treated:

Leukemia and lymphoma

Eligibility:

  • 21 years of age or younger
  • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
  • Has not been previously treated
View Trial

TINI: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL)

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

  • Newly diagnosed ALL
  • 1 year of age or younger at the time of diagnosis
  • Has not had any — or has had limited — prior therapy
  • Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome
View Trial

TOTXVI: Total Therapy Study XVI For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Diseases Treated:

Acute Lymphoblastic Leukemia

Eligibility:

  • 18 years of age or younger
  • Newly diagnosed acute lymphoblastic leukemia (ALL)
View Trial

TSALV: Advanced Chemotherapy Treatment for Relapsed Leukemia or Lymphoma in Children

Diseases Treated:

Leukemia, Lymphoma

Eligibility:

  • T-call acute lymphoblastic leukemia or lymphoma that has:
    • Come back after treatment the first time or
    • Did not respond to treatment the first time
  • 21 years or younger
  • Able to swallow capsules
View Trial

Collaborative Clinical Trials

ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Diseases Treated:

Relapsed or refractory solid tumors or anaplastic large cell lymphoma

Eligibility:

  • Participant is > than 12 month and < 21 years of age at the time of enrollment.
  • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
  • Participant does not have primary or metastatic CNS tumor.
  • Participant has not received prior therapy with crizotinib.
View Trial

HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

Diseases Treated:

Lymphocyte predominant Hodgkin lymphoma 

Eligibility:

  • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
  • LPHL that has not been previously treated with chemotherapy or radiation therapy
  • 18 years of age or younger

 

View Trial

LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Diseases Treated:

For survivors of Hodgkin lymphoma

Eligibility:

  • Females, 25 years of age or older.
  • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
View Trial

NECTAR: Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Diseases Treated:

Leukemia

Eligibility:

  • Patients must be ≥ 1 and ≤ 21 years of age at the time of study enrollment.
  • Patients must have first relapse T-cell ALL or T-cell lymphoblastic lymphoma.
  • Patients with T-cell ALL must have greater than 25% blasts in the bone marrow with or without extramedullary disease.
  • Patients with T-cell ALL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis.
View Trial